 As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc NYSE: AMRX. The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral to Buy with a 5.50 price target. 